E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury |
|
E.1.1.1 | Medical condition in easily understood language |
Lower limb or combined lower limb and upper limb spasticity due to stroke or traumatic brain injury |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10058977 |
E.1.2 | Term | Spastic paresis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of the efficacy and safety of 400 U of NT 201 in the treatment of adult lower limb spasticity involving the ankle plantar flexors. |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of the long-term safety of NT 201 in the treatment of spasticity with total body doses up to 800 U. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Main inclusion criteria • Female or male subject ≥ 18 years and ≤ 85 years at screening • Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury • Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus • Modified Ashworth Scale-Bohannon [MAS] score of 2 or 3 points in the ankle plantar flexor of the target lower limb (supine position, knee extended) • Minimum passive range of motion in ankle of the target lower limb (supine position, knee extended): 10°dorsiflexion and 20°plantarflexion • At least 4 months since last botulinum neurotoxin [BoNT] injection for treatment of spasticity or any other condition • For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an: o Activated partial thromboplastin time [aPTT] ≤ 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or o International normalized ratio [INR] value of ≤ 2.5 (subjects on coumarins or other anticoagulants monitored by INR)
Main eligibility criteria for re-injection • According to the experience-based opinion of the investigator, the subject must have a clinical need for 400 U of NT 201 in the affected lower limb • Body weight at least 50 kg • Negative urine pregnancy test for women of childbearing potential • For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an: o aPTT ≤ 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or o INR value of ≤ 2.5 (subjects on coumarins or other anticoagulants monitored by INR) • No infection or inflammation in the area of the planned injection sites at the visits |
|
E.4 | Principal exclusion criteria |
Main exclusion criteria • Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert Eaton syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study • Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity • Body weight < 50 kg • Severe atrophy of the target limb muscles • Previous, ongoing or planned treatments of spasticity with intrathecal baclofen • Previous, ongoing, or planned treatments of spasticity in the target lower limb with any of the following procedures: o Surgical intervention o Alcohol or phenol block o Muscle afferent block • Physiotherapy or use of orthoses or splints at the target limb initiated less than 4 weeks before screening or expected to change during the double blind phase of the study • Current or planned treatment with parenterally administered drugs that interfere with neuromuscular transmission (e.g. intrathecal baclofen, tubocurarine type muscle relaxants used in anesthesia),, or local anesthetics in the treated region within 2 weeks prior to screening • Infection or inflammation at the injection sites • Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory tract infections, or compromised respiratory function as per investigator's clinical judgment • Pregnancy (as verified by a positive pregnancy test) or breast feeding |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Co-primary efficacy variables: • Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at Weeks 4 to 6
Primary safety variable: Occurrence of treatment emergent adverse events [TEAEs] in Main Period |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Timepoints of evaluation of Co-primary efficacy variables: • Modified Ashworth Scale-Bohannon (MAS) ankle score at baseline to Weeks 4 to 6
Timepoint of evaluation of the primary safety variable: • Baseline to week 12 |
|
E.5.2 | Secondary end point(s) |
Key secondary efficacy variable: • Change from Study Baseline in Goal Attainment Scale [GAS] at Week 6
Other secondary efficacy variables: • Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6 • Global Impression of Change Scale (GICS) assessed by subject at Week 4 to 6 • Global Impression of Change Scale (GICS) assessed by caregiver at Week 4 to 6 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Goal Attainment Scale [GAS] at Week 4 to 6 • GICS assessed by physician at week 4 to 6 • GICS assessed by subject at Week 4 to 6 • GICS assessed by caregiver at Week 4 to Week 6. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 43 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
Ukraine |
Canada |
United Kingdom |
United States |
Belgium |
Czechia |
France |
Germany |
Hungary |
Italy |
Poland |
Slovakia |
Spain |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS The End of the entire study, is defined as the date of attendance of the last subject of the final visit of the OLEX period (V17 for subjects with five cycles or V20 with six cycles). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |